William Blair analyst Ryan Daniels has reiterated their bullish stance on PRVA stock, giving a Buy rating on August 19.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Daniels has given his Buy rating due to a combination of factors including Privia Health Group’s impressive performance in the Medicare Shared Savings Program (MSSP). The company achieved a significant increase in shared savings for the 2024 performance year, which led to an upward revision of their 2025 adjusted EBITDA guidance. This reflects strong operational execution and financial health.
Furthermore, Daniels views Privia Health as a key player in the healthcare sector poised for substantial growth. The company’s scalable business model and positive macroeconomic factors are expected to drive significant expansion in revenue and profitability. The stock is considered undervalued relative to its market leadership and growth potential, making it an attractive investment opportunity.
In another report released on August 19, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $24.00 price target.